Patents by Inventor Kanda Ramasamy

Kanda Ramasamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis and use of 2?-substituted-N6-modified nucleosides
    Patent number: 8575331
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: November 5, 2013
    Assignee: Valeant Pharmaceuticals North America
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • SYNTHESIS AND USE OF 2'-SUBSTITUTED-N6-MODIFIED NUCLEOSIDES
    Publication number: 20110196144
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Application
    Filed: September 7, 2010
    Publication date: August 11, 2011
    Applicant: Valeant Pharmaceuticals North America
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • Synthesis and use of 2?-substituted-N-modified nucleosides
    Patent number: 7799908
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: September 21, 2010
    Assignee: Valeant Pharmaceuticals North America
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE
    Publication number: 20090176721
    Abstract: Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Application
    Filed: March 9, 2009
    Publication date: July 9, 2009
    Applicant: Valeant Pharmaceuticals North America
    Inventors: Robert Tam, Kanda Ramasamy, Zhi Hong, Johnson Lau
  • Synthesis for hydroxyalkylated heterocyclic bases
    Patent number: 7371857
    Abstract: A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: May 13, 2008
    Assignee: Valeant Research & Development
    Inventors: Kanda Ramasamy, Jean-Luc Girardet, Haoyun An, Zhi Hong, Robert Orr
  • Synthesis for hydroxyalkylated heterocyclic bases
    Publication number: 20060135768
    Abstract: A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.
    Type: Application
    Filed: August 8, 2002
    Publication date: June 22, 2006
    Applicant: RIBAPHARM INC.
    Inventors: Kanda Ramasamy, Jean-Luc Girardet, Haoyun An, Zhi Hong, Robert Orr
  • Synthesis and use of 2'-substituted-n6-modified nucleosides
    Publication number: 20060135465
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Application
    Filed: January 15, 2004
    Publication date: June 22, 2006
    Applicant: Valeant Research & Development
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • Tirazole nucleoside analogs and methods for using same
    Patent number: 7056895
    Abstract: Novel heterocyclic aromatic compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: June 6, 2006
    Assignee: Valeant Pharmaceuticals International
    Inventors: Kanda Ramasamy, Robert Tam
  • Nucleoside analogs with carboxamidine modified monocyclic base
    Publication number: 20050159372
    Abstract: Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Application
    Filed: August 22, 2002
    Publication date: July 21, 2005
    Inventors: Robert Tam, Kanda Ramasamy, Zhi Hong, Johnson Lau
  • Nucleoside compounds and uses thereof
    Patent number: 6815542
    Abstract: Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: November 9, 2004
    Assignee: Ribapharm, Inc.
    Inventors: Zhi Hong, Jean-Luc Girardet, Kanda Ramasamy, Johnson Lau
  • Nucleoside compounds and uses thereof
    Publication number: 20040002596
    Abstract: Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Application
    Filed: December 13, 2002
    Publication date: January 1, 2004
    Inventors: Zhi Hong, Jean-Luc Girardet, Kanda Ramasamy, Johnson Lau
  • Monocyclic L-nucleosides, analogs and uses thereof
    Patent number: 6642206
    Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.
    Type: Grant
    Filed: April 9, 2002
    Date of Patent: November 4, 2003
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Kanda Ramasamy, Robert Tam, Devron Averett
  • Monocyclic L-nucleosides, analogs and uses thereof
    Publication number: 20030018186
    Abstract: Novel monocyclic L-Nucleoside compounds have the general formula 1
    Type: Application
    Filed: April 9, 2002
    Publication date: January 23, 2003
    Inventors: Kanda Ramasamy, Robert Tam, Devron Averett
  • Heterocyclic aromatic compounds and uses thereof
    Publication number: 20020156030
    Abstract: Novel heterocyclic aromatic compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Application
    Filed: March 11, 2002
    Publication date: October 24, 2002
    Inventors: Kanda Ramasamy, Robert Tam
  • L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
    Patent number: 6455690
    Abstract: Novel nucleosides having the structure of Formula 1 and Formula 2 are contemplated. In one aspect of the invention, controlled release dosage forms are particularly contemplated. Further, alternative routes of administration of the nucleosides having the structure of Formula 1 or Formula 2 are contemplated.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: September 24, 2002
    Inventors: Robert Tam, Devron Averett, Guangyi Wang, Kanda Ramasamy